

CLINICAL PATHWAY/GUIDELINE/SCP APPROVAL CHECKLIST

Please note: All questions on the checklist are mandatory for the purpose of ratification of the submitted guideline/protocol/policy and must be completed in full including comments.

including comments.	including comments.								
SECTION 1: GENERAL INFORMATION ABOUT CLINICAL PATHWAY/GUIDELINE									
Document title:									
Yes: □ No: □			ocument supersede or replace an existing one? y/guideline being replaced below:						
IDENTIFICATION OF NEED	YES	NO	EVIDENCE/COMMENTS						
Why has this guidance been developed?		vide ails							
Has the need/requirement for this guidance been established by the NY&Y APC?									
Is the need/requirement for this guidance responding to a Patient Safety Alert, NICE guidance, other national best practice, external agency report, Serious Incident or other? If update of existing guidelines reestablish need for guideline.									
Has this guidance been supported at the specialities in both HDFT and YSFT?									
IMPLEMENTATION AND COMMUNICATION									
Explain how the guidance will be communicated and implemented	Provide Details								
AUDIT AND MONITORING									
Please describe how this guidance will be monitored for compliance	Provide Details								
RISK/BENEFIT AND COST/BENEFIT	YES	NO	EVIDENCE/COMMENTS						
Is there a description of the health (or other) benefits anticipated as a result of the implementation of this guidance?									
Is there a description of the possible harm or risk that may result from implementation?									



CLINICAL PATHWAY/GUIDELINE/SCP APPROVAL CHECKLIST

Are there financial and resource implications of guidance		
implementation? Does this guidance have		
implications for primary care? If yes, who was it discussed with in	Provide	
primary care?	Details	
Are any individuals involved in		
other interests (financial or otherwise), one of which could		
possibly affect the motivation or		
decision-making?		
Evidence search: Has the search		
strategy been recorded? REVIEWS		EVIDENCE/COMMENTS
		EVIDENCE GOMMENTO
Who will be responsible for future review of the guidance? (usually	Provide	
the lead author)	Details	
CHECKLIST COMPLETED BY		Date
Insert Name	Provide	
	Details	
Resubmission Date		
Lead Author:		
Details of working/developn		
Name	Job title	e Organisation
SECTION 3: CONSULTAT	ION PROC	ESS
Details of Consultation		
(min NY&Y MMT, YFT and	HDFT to be	e consulted – comments received see appendix)
Name	Job title	e Organisation



CLINICAL PATHWAY/GUIDELINE/SCP APPROVAL CHECKLIST

SECTION 4: CHECKLIST

Note that the sources recommended to be checked are not exhaustive. Depending on the subject of the document, there may be other resources that would be useful to check. These should be recorded appropriately.

Criteria				Comments
Checked against the relev BNF and /or BNFC?	ant sections of the electronic			
Checked against the relev Characteristics?	ant Summary of Product			
Checked for any related d	rug safety warnings?			
Checked against relevant Technology Appraisals? If				
Checked against decisions from other national bodies e.g. SMC, AWMSG, etc.				
Relevant and comprehens literature using Embase at				
Other relevant sources che society websites? If so, sta				
Includes all relevant clinica (See NHSE guidance and information required for a	RMOC for minimum			
	mmendations are consistent , highlight any discrepancies			
The text in the document or references?	can be verified from the			
All hyperlinks in the docun	nent are working?			
The text has been checked for: a) typographical errors (the spell check facility should be used) b) grammatical errors				
c) clarity				
d) good flow of English				
e) accessibility, font size, spacing, colour Consultation Comments reviewed, incorporated and				
checked against evidence where necessary				
1 st checker:		Date	checked:	
Final checker (pharmacist):		Date checked:		